Amgen profit doubles over 2011
Biotech drug maker Amgen Inc. said Tuesday that its third-quarter profit more than doubled from a year ago, when a huge legal reserve charge weighed down results. It trounced Wall Street expectations and raised its profit forecast sharply. The maker of anemia drugs Aranesp and Epogen said net income was $1.11 billion, or $1.41 per share. That’s up from $454 million, or 50 cents a share, in 2011’s third quarter.